Metraipolis › archive › dc_756074026fe8

Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction — Europe PMC PMID:41473431

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41473431
DOI
10.3389/fonc.2025.1631286
License (as archived)
solo-consultazione
Archived
2026-11-07T15:39:09.763Z
SHA-256 of the archived text
1bb0b256cf6200ab85c7ae642b83c80739054e2489d2193678de3a049ade10fc
Stable URL of this page
https://metraipolis.com/documento/dc_756074026fe8

How to cite

Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction — Europe PMC PMID:41473431 — Europe PMC (en), https://europepmc.org/article/MED/41473431 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_756074026fe8 (Metraipolis archive dc_756074026fe8, sha256 1bb0b256cf6200ab85c7ae642b83c80739054e2489d2193678de3a049ade10fc)
BibTeX
@misc{dc756074026fe8,
  title = {Case Report: Biweekly TAS-102 and bevacizumab as maintenance therapy for recurrent and metastatic pseudomyxoma peritonei following palliative cytoreduction — Europe PMC PMID:41473431},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41473431},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_756074026fe8; sha256 1bb0b256cf6200ab85c7ae642b83c80739054e2489d2193678de3a049ade10fc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41473431. Agents can read the archived copy with the MCP tool read_document.